The global autoimmune disease diagnosis market reached a value of US$ 4.4 Billion in 2020. An autoimmune disease refers to a condition wherein the immune system attacks and destroys healthy cells, tissues, and organs of the body. In the longer run, it can also lead to abnormal growth of an organ and changes in organ function. Currently, more than 80 different autoimmune disorders have been identified by scientists, out of which Systemic Lupus Erythematosus (SLE), multiple sclerosis, rheumatoid arthritis, and type I diabetes, are the most common. Depending on the disorder, the doctor uses a combination of methods, which include a physical examination, medical history, blood tests, biopsy, and X-rays, to provide an effective diagnosis. They prescribe anti-inflammatory and immunosuppressant drugs, physical therapy, surgery, and injections, to control the overactive immune response and provide relief from symptoms.
Owing to the rising prevalence of autoimmune diseases, healthcare professionals around the world are focusing on the adoption of advanced technologies to conduct multiple tests with faster and more precise results. Apart from this, a large number of research and diagnostics institutes are undertaking public awareness campaigns to educate individuals about autoimmune diseases and their possible treatments and diagnosis, which is positively influencing the market growth. Furthermore, several governing authorities, along with non-governing organizations, are funding various programs to develop novel therapeutics. For instance, the AMP RA/SLE Program, launched by the Accelerating Medicines Partnership (AMP), is a public-private partnership between the National Institutes of Health (NIH), the US Food and Drug Administration (FDA) and multiple non-profit organizations. The program aims to identify relevant drug targets for the treatment of autoimmune diseases. Looking forward, IMARC Group expects the global autoimmune disease diagnosis market to grow at a CAGR of 8.10% during 2021-2026.
Breakup by Product Type:
Breakup by Disease Type:
Breakup by Test Type:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Aesku.Diagnostics GmbH & Co. KG, Beckman Coulter Inc. (Danaher Corporation), bioMérieux SA (Institut Mérieux), Bio-Rad Laboratories Inc., Euroimmun AG (PerkinElmer Inc.), Hemagen Diagnostics Inc., Inova Diagnostics Inc. (Werfen Group S.A.), Myriad Genetics Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG (Siemens AG), SQI Diagnostics, Thermo Fisher Scientific Inc., Trinity Biotech, etc.
The global autoimmune disease diagnosis market size was valued at US$ 4.40 Billion in 2020.
According to the estimates by IMARC Group, the global autoimmune disease diagnosis market is expected to witness a CAGR of 8.10% from 2021 to 2026.
The rising adoption of numerous advanced technologies to conduct multiple tests simultaneously with faster and accurate results represents one of the key drivers for the global autoimmune disease diagnosis market.
The increasing investments in extensive R&D activities for introducing novel therapeutic solutions represent one of the key industry trends in the global autoimmune disease diagnosis market.
Sudden outbreak of the COVID-19 pandemic had led to the avoidance of numerous elective diagnosis procedures, including blood tests, biopsy, X-rays, physical therapy, etc., for reducing the risk of coronavirus infection upon interaction with healthcare professionals or equipment.
On the basis of the product type, the market has been bifurcated into consumables and assay kits, and instruments. Currently, consumables and assay kits hold the majority of the total market share.
On the basis of the disease type, the market has been divided into systemic autoimmune disease and localized autoimmune disease. Among these, localized autoimmune disease represents the largest segment.
On the basis of the test type, the market has been classified into routine laboratory tests, inflammatory markers, autoantibodies and immunologic tests, and others. Among these, routine laboratory tests hold the largest market share.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where Europe dominates the global market.
The key companies in the global autoimmune disease diagnosis market are Abbott Laboratories, AESKU.GROUP, Danaher Corp., bioMérieux SA, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Hemagen Diagnostics, Inc., Inova Diagnostics, Inc., Myriad Genetics, Inc., Quest Diagnosis Incorporated, Siemens Healthineers AG, SQI Diagnostics, Thermo Fisher Scientific Inc., Trinity Biotech plc., etc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at